Failure of Achieving Tacrolimus Target Blood Concentration Might Be Avoided by a Wide Genotyping of Transplanted Patients: Evidence from a Retrospective Study.
immunosuppressant
pharmacogenetics
polymorphism
tacrolimus
therapeutic drug monitoring
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
01 Jun 2020
01 Jun 2020
Historique:
received:
28
04
2020
revised:
22
05
2020
accepted:
29
05
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
epublish
Résumé
Precise tacrolimus treatment in transplanted patients is achieved in the clinical setting by performing therapeutic drug monitoring (TDM) and consequently adjusting therapy. The aim of this study was to retrospectively analyze the variability in tacrolimus blood levels throughout 2 years of observation in 75 transplanted patients and to investigate if tacrolimus blood levels correlate with presence of genetic polymorphisms, thus modifying tacrolimus pharmacokinetics. CYP3A5*1 (G6986A), CYP3A4*1B (A392G), CYP3A4*22, ABCB1 (C3435T; C1236T; G2677A/T), SLCO1B1 (T521C), polymorphisms were analyzed. Based on the effect of their genotypes, patients were stratified into 5 groups: (1) reduced tacrolimus metabolism (RM), (2) increased metabolism (IM), (3) transporters polymorphisms (TM), (4) metabolism and transporter polymorphisms (AM) and (5) no mutations (Wild Type, WT). The percentage of the samples out of therapeutic range was significantly higher in the IM group than in the WT group (
Identifiants
pubmed: 32492825
pii: jpm10020047
doi: 10.3390/jpm10020047
pmc: PMC7354451
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Transplantation. 1996 Oct 15;62(7):920-6
pubmed: 8878385
Expert Opin Pharmacother. 2008 Mar;9(4):635-43
pubmed: 18312164
Transplant Proc. 2010 Oct;42(8):3031-3
pubmed: 20970601
Nat Genet. 2001 Apr;27(4):383-91
pubmed: 11279519
Clin Pharmacol Ther. 2003 Sep;74(3):245-54
pubmed: 12966368
Clin Pharmacokinet. 2014 Feb;53(2):123-39
pubmed: 24249597
Clin Pharmacol Ther. 1999 Sep;66(3):288-94
pubmed: 10511065
Pharmacogenet Genomics. 2008 Apr;18(4):339-48
pubmed: 18334918
Clin Chem. 2011 Nov;57(11):1574-83
pubmed: 21903774
Clin Pharmacol Ther. 2001 Jan;69(1):24-31
pubmed: 11180035
Transplantation. 2005 Feb 27;79(4):499-502
pubmed: 15729180
Clin Pharmacokinet. 2010 Mar;49(3):141-75
pubmed: 20170205
Pharmacogenetics. 2003 Aug;13(8):481-94
pubmed: 12893986
Pharmacogenet Genomics. 2006 Sep;16(9):659-65
pubmed: 16906020
Ther Drug Monit. 2005 Dec;27(6):819-21
pubmed: 16306861
Pharmacogenet Genomics. 2007 Oct;17(10):873-83
pubmed: 17885626
Ther Drug Monit. 2013 Jun;35(3):328-31
pubmed: 23666583
Clin Pharmacol Ther. 2002 Mar;71(3):196-204
pubmed: 11907494
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8
pubmed: 10716719
Clin J Am Soc Nephrol. 2007 Mar;2(2):374-84
pubmed: 17699437
Nephrol Dial Transplant. 2011 Sep;26(9):3046-50
pubmed: 21677300
Clin Chim Acta. 2012 Sep 8;413(17-18):1326-37
pubmed: 21996082
Pharmacogenomics. 2011 Oct;12(10):1383-96
pubmed: 21902502
Pharmacogenetics. 2001 Dec;11(9):773-9
pubmed: 11740341
Clin Pharmacokinet. 2012 Mar 1;51(3):175-86
pubmed: 22339449
Transplantation. 2002 Dec 15;74(11):1486-9
pubmed: 12490779
Ther Drug Monit. 2010 Aug;32(4):394-404
pubmed: 20526235
Clin Pharmacol Ther. 2000 Jul;68(1):82-91
pubmed: 10945319
Ther Drug Monit. 2007 Aug;29(4):412-6
pubmed: 17667794
Ther Drug Monit. 2009 Apr;31(2):139-52
pubmed: 19177031
Clin Pharmacokinet. 2004;43(10):623-53
pubmed: 15244495
J Am Soc Nephrol. 2003 Jul;14(7):1889-96
pubmed: 12819250
PLoS One. 2015 Mar 24;10(3):e0122745
pubmed: 25803854
Pharm Res. 2004 Jun;21(6):904-13
pubmed: 15212152
Transpl Int. 2012 Apr;25(4):471-80
pubmed: 22369694